Svar Life Science

November 29, 2023

Introducing iLite® AAV NAb platform for Immunogenicity testing

Reliable detection of AAV Neutralizing Antibodies in human serum samples with proven iLite technology


Do you want to know how silent your AAV capsid transfer is?

In the field of gene therapy, the ability of Adeno-associated virus (AAVs) vectors to deliver therapeutic genes without detection by the immune system is key.

Nevertheless, the presence of Neutralizing Antibodies (NAbs) can create immune barriers, which can hinder the efficacy of AAV-based therapy. Therefore, detecting NAbs is essential to overcome roadblocks in the development of AAV-based human gene therapies.

 

Assessing the "silence” of an AAV capsid is critical for the development of effective gene therapies. 

That's why we are excited to introduce our unique iLite® AAV NAb platform for different AAV serotypes!

November 29, 2023

Introducing iLite® AAV NAb platform for Immunogenicity testing

Reliable detection of AAV Neutralizing Antibodies in human serum samples with proven iLite technology


Do you want to know how silent your AAV capsid transfer is?

In the field of gene therapy, the ability of Adeno-associated virus (AAVs) vectors to deliver therapeutic genes without detection by the immune system is key.

Nevertheless, the presence of Neutralizing Antibodies (NAbs) can create immune barriers, which can hinder the efficacy of AAV-based therapy. Therefore, detecting NAbs is essential to overcome roadblocks in the development of AAV-based human gene therapies.

 

Assessing the "silence” of an AAV capsid is critical for the development of effective gene therapies. 

That's why we are excited to introduce our unique iLite® AAV NAb platform for different AAV serotypes!

The iLite® AAV NAb platform is a powerful tool specifically designed to accurately assess the presence and impact of NAb levels in human and non-human primate (NHP) serum samples. With our proven iLite technology, this platform offers a robust, streamlined, and specific assessment of NAb neutralizing capacity for different AAV serotypes (2,5,6,8 and 9). It offers great possibilities for customization for any hybrid or chimeric capsid, ultimately enhancing the efficacy and safety of your AAV-based gene therapy.

Say goodbye to the stress of cumbersome and inconsistent NAb measurements, and hello to the peace of mind of accurate and reliable results. Let us help you take the first step towards uncovering the silence of your AAV with the iLite AAV NAb platform!

 


Neutralizing antibodies recognize and neutralize the transduction of Adeno-associated viruses (AAVs). These antibodies bind to specific structures on the surface of AAVs, preventing them from infecting host cells and potentially inducing unwanted immune responses

 


Key features of our new iLite AAV NAb platform :

 

Semiquantitative NAb Assessment with Unmatched Precision

A two-component system consisting of a packaging AAV serotype-producing cell and a responsive reporter cell provides a well-controlled system that can accurately provide a semiquantitative NAb assay. With firefly luciferase reporter gene expression proportional to the level of AAV transduction, you can determine the inhibition of AAV transduction and the presence of neutralizing antibodies against AAV with unmatched precision.

Elimination of the Need for Vector Production 

The need for vector purification is eliminated with integrated AAV production carried out by the packaging cell within the two-component system, saving you time and cost and resulting in a reduction of lot-to-lot variation on the transduction of the vector.

Detection of Matrix Effects

The constitutive Renilla reporter gene in the responsive cell enables the assay to identify sera containing functionally interfering factors, making the AAV NAb platform well equipped for serum matrix effect and detection of false positive samples.

Consistency in Every Vial for Reproducible Results

The assay-ready format of the AAV NAb platform ensures consistent cell numbers collected and frozen at the same passage in each vial, enabling reliable and reproducible experiments every time.

Plating to Luciferase Readout Overnight!

The assay-ready effector and responsive cells allow for a short turnaround time of just overnight from plating the cells to results, allowing for efficient and timely assessment of NAb.

Realize Any Immunogenicity Project You Need

The modular setup of the assay enables us to customize for any capsid of interest, including hybrid and chimeric capsids.

We also offer CRO services, with advanced analytical methods and expert knowledge in AAV-induced immunogenicity, potency, and complex analytics methods, including TK assay for therapeutics administered as gene products.

Let our experts handle your samples in an AAV project tailored to meet your specific needs!

 

This powerful tool empowers you to uncover the silence of your vector and optimize strategies to overcome immune barriers to enhance the efficacy and safety of AAV-based gene transfer.

Learn more about our new iLite AAV NAb platform!

 

 

TRUSTED BY SCIENTISTS, PROVEN BY RESULTS!

“The iLite® technology, with its proven track record in measuring NAbs against biological drugs, is a great tool to evaluate the ability of antibodies to block AAV transgene expression.”
Dr. Ulrich Mayer,  Global Technology Manager, Cell-based solutions